CoChat

Oncogenic B-RAF Signaling in Melanoma Impairs the Therapeutic Advantage of Autophagy Inhibition

Open access
Armstrong, Jane L., Corazzari, Marco, Martin, Shaun, Pagliarini, Vittoria, Falasca, Laura, Hill, David S., Ellis, Nicola, Al Sabah, Salim, Redfern, Christopher P.F., Fimia, Gian Maria, Piacentini, Mauro, Lovat, Penny E. · 2011 · Clinical Cancer Research

Published version of a preprint

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Purpose: Metastatic melanoma is characterized by extremely poor survival rates and hence novel therapies are urgently required. The ability of many anticancer drugs to activate autophagy, a lysosomal-mediated catabolic process which usually promotes cell survival, suggests targeting the autophagy pathway may be a novel means to augment therapy. Experimental Design: Autophagy and apoptosis were assessed in vitro in human melanoma cell lines in response to clinically achievable concentrations of the endoplasmic reticulum (ER) stress-inducing drugs fenretinide or bortezomib, and in vivo using a s.c. xenograft model. Results: Autophagy was activated in response to fenretinide or bortezomib in B-RAF wild-type cells, shown by increased conversion of LC3 to the autophagic vesicle-associated form (LC3-II) and redistribution to autophagosomes and autolysosomes, increased acidic vesicular organelle formation and autophagic vacuolization. In contrast, autophagy was significantly reduced in B-RAF–mutated melanoma cells, an effect attributed partly to oncogenic B-RAF. Rapamycin treatment was unable to stimulate LC3-II accumulation or redistribution in the presence of mutated B-RAF, indicative of de-regulated mTORC1-dependent autophagy. Knockdown of Beclin-1 or ATG7 sensitized B-RAF wild-type cells to fenretinide- or bortezomib-induced cell death, demonstrating a pro-survival function of autophagy. In addition, autophagy was partially reactivated in B-RAF–mutated cells treated with the BH3 mimetic ABT737 in combination with fenretinide or bortezomib, suggesting autophagy resistance is partly mediated by abrogated Beclin-1 function. Conclusions: Our findings suggest inhibition of autophagy in combination with ER stress-inducing agents may represent a means by which to harness autophagy for the therapeutic benefit of B-RAF wild-type melanoma. Clin Cancer Res; 17(8); 2216–26. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-3003

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 65

Metadata

Authors
Armstrong, J. L., Corazzari, M., Martin, S., Pagliarini, V., Falasca, L., Hill, D. S., Ellis, N., Al Sabah, S., Redfern, C. P. F., Fimia, G. M., Piacentini, M., & Lovat, P. E.
Affiliations
  • Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (IT)
  • Authors' Affiliations: 1Dermatological Sciences, Institute of Cellular Medicine, Medical School, and 2Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne, UK; 3National Institute for Infectious Disease, ‘L. Spallanzani’, and 4University of Tor Vergata, Rome, Italy
Corresponding author
Lovat, Penny E.
Venue
Clinical Cancer Research
Published
2011-04-14
Volume
17
Issue
8
Pages
2216-2226
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2122402825
Cited by
65
References
49
Citations by year
2026: 1 · 2023: 2 · 2022: 1 · 2021: 7 · 2020: 4 · 2019: 2 · 2018: 5 · 2017: 2 · 2016: 6 · 2015: 7 · 2014: 8 · 2013: 12 · 2012: 3
FWCI
6.75
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
  • AIRUS (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Funders
  • Abbott Laboratories
  • JGW Patterson Foundation
  • British Skin Foundation
  • Newcastle University
  • European Commission
  • Fondazione Telethon
  • Ministero della Salute
  • Associazione Italiana per la Ricerca sul Cancro
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Calcium signaling and nucleotide metabolism
Keywords
melanoma, BRAF mutation, autophagy, autophagy inhibition, endoplasmic reticulum stress, fenretinide, bortezomib, LC3-II, Beclin-1, ATG7, ABT-737, BH3 mimetics, mTORC1, apoptosis, rapamycin, combination therapy
MeSH terms
Bortezomib, Animals, Antineoplastic Combined Chemotherapy Protocols, Autophagy, Biphenyl Compounds, Boronic Acids, Endoplasmic Reticulum, Female, Humans, Luminescent Proteins, Melanoma, Microscopy, Fluorescence, Microtubule-Associated Proteins, Nitrophenols, Piperazines, Pyrazines, Sulfonamides, Blotting, Western, Signal Transduction, Apoptosis, Fenretinide, Xenograft Model Antitumor Assays, RNA Interference, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oncogenic B-RAF Signaling in Melanoma Impairs the Therapeutic Advantage of Autophagy Inhibition. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-3003
The paper
Armstrong, J. L., Corazzari, M., Martin, S., Pagliarini, V., Falasca, L., Hill, D. S., Ellis, N., Al Sabah, S., Redfern, C. P. F., Fimia, G. M., Piacentini, M., & Lovat, P. E. (2011). Oncogenic B-RAF Signaling in Melanoma Impairs the Therapeutic Advantage of Autophagy Inhibition. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-3003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.